Cabaletta Bio Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
CABA$1.45-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(52,649) | $(30,341) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 8,804 | 5,283 |
| Depreciation | 819 | 735 |
| Non-cash lease expense | 3,186 | 915 |
| Accretion of lease liabilities | 393 | 198 |
| Amortization of discount on investments | (1,169) | (186) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 210 | 1,043 |
| Other assets | (543) | (120) |
| Accounts payable | 317 | (145) |
| Accrued and other current liabilities | (1,925) | (740) |
| Lease liabilities | (2,220) | (1,139) |
| Net cash used in operating activities | (44,777) | (24,497) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (1,582) | (437) |
| Purchases of investments | — | (48,085) |
| Proceeds from maturities of investments | 24,500 | 25,000 |
| Net cash provided by (used in) investing activities | 22,918 | (23,522) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock, net of issuance costs | 5,746 | 93,604 |
| Proceeds from issuance of common stock in connection with the exercise of stock options | 1,359 | 848 |
| Proceeds from issuance of common stock under employee stock purchase plan | 129 | 32 |
| Net cash provided by financing activities | 7,234 | 94,484 |
| Net (decrease) increase in cash and cash equivalents | (14,625) | 46,465 |
| Cash and cash equivalents—beginning of period | 193,238 | 81,607 |
| Cash and cash equivalents—end of period | $178,613 | $128,072 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Issuance costs included in accrued expenses | $— | $142 |
| Property and equipment purchases included in accounts payable and accrued expenses | $375 | $23 |
| Right-of-use assets obtained in exchange for lease obligations | $4,210 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.